Endothelium-derived nitric oxide contributes to the vasorelaxant response induced by mesoionic 2-(4-chlorophenyl)-3-methyl-4-(4-methoxyphenyl)-1;3- thiazolium-5-thyolate (CMMTT) in rats

Journal of Pharmacological Sciences

Volumn 110, Issue 1, 2009, Pages 29-35

  Cavalcante, Karla Veruska Marques ^a   Correia, Nádja De Azevedo ^a   Dias, Katy Lísias Gondim ^a   Silva, Darizy Flávia ^a   Silva Filho, José Couras ^a   Araújo, Islania Giselia Albuquerque ^a   Lira, Bruno Farias ^a   Athayde Filho, Petrônio ^a   Medeiros, Isac Almeida ^a  

^a FEDERAL UNIVERSITY OF PARAÍBA   (Brazil)

Author keywords

Mesoionic compound; Nitric oxide (NO); NO cGMP pathway; Superior mesenteric artery; Vasodilation

Indexed keywords

2 (4 CHLOROPHENYL) 3 METHYL 4 (4 METHOXYPHENYL) 1,3 THIAZOLIUM 5 THIOLATE; AMPHOLYTE; CYCLIC GMP; NITRIC OXIDE; UNCLASSIFIED DRUG;

ANIMAL TISSUE; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFECT; DRUG RESPONSE; MALE; MESENTERIC ARTERY; NONHUMAN; RAT; VASCULAR ENDOTHELIUM; VASODILATATION;

EID: 66349098419     PISSN: 13478613     EISSN: 13478648     Source Type: Journal    
DOI: 10.1254/jphs.FP0071581     Document Type: Article

References (50)

1. Lira BF, Athayde-Filho PF, Miller J, Simas AM, Dias AF, Vieira MJ. Synthesis and characterization of some new mesoionic 1,3-thiazolium-5-thiolates via cyclodehydration and in situ 1,3-dipolar cycloaddition/cycloreversion. Molecules. 2002;7:791-800. (Pubitemid 38982499)
2. Kier LB, Roche EB. Medicinal chemistry of the mesoionic compounds. J Pharm Sci. 1967;56:148-169.
3. Corell T, Pedersen SB, Lissau B, Moilanen E, Metsä-Ketelä T, Kankaanranta H, et al. Pharmacology of mesoionic oxatriazole derivatives in blood, cardiovascular and respiratory systems. Pol J Pharmacol. 1994;46:553-566.
4. Rehse K, Ciborski T, Müller B. Platelet aggregation inhibiting and anticoagulant effect of oligoamines. XXVII: inhibition of leucocyte adherence to endothelium by oligoamine RE 1492C and the NO-donor RE 2047. Arch Pharm (Weinheim). 1995;328:25-126.
5. Satyanarayana K, Rao MNA. Synthesis and anti-inflamatory, analgesics and antipyretics testing of 4-[1-oxo-(3-substituted arly)-2-propenyl]-3- phenylsydnones and of 3-[4-[3-(substituted arly)-1-oxo-2-propenyl] phenyl] sydnones. J Pharmacol Sci. 1995;84:263-266.
6. Daly JW, Hong O, Padgett WL, Shamim MT, Jacobson KA, Ukena D. Non-xanthine heterocycles: activity as antagonists of A1- and A2-adenosine receptors. Biocheml Pharmacol. 1988;37:655-664.
7. Glennon RA, Tejani-Butt SM, Padgett W, Daly JW. Mesoionic xanthine analogues: antagonists of adenosine receptors. J Med Chem. 1984;27:1364-1367. (Pubitemid 14032257)
8. Walker KA, Sjogren EB, Matthews TR. Antitrichomonal activity of mesoionic thiazolo [3,2-a] pyridines. J Med Chem. 1985;28:1673-1679. (Pubitemid 16204836)
9. Rehse K, Martens A. Platelet aggregation inhibiting and anticoagulants effects of oligoamines, XXI - 4,4′-Alkylene-bissydnone imines. Arch Pharm (Weinheim). 1993;326:307-311.
10. Hellberg M, Stubbins JF, Glennon RA. Preliminary investigation of mesoionic xanthine analogues as inhibitors of platelet aggregation. Bioorg Med Chem. 2000;8:1917-1923. (Pubitemid 30612482)
11. Ehlhardt WJ, Wheeler WJ, Breau AP, Chay SH, Birch GM. Biotransformation of the antiviral agent 1,3,4-thiadiazol-2-ylcyanamide (LY217896) and characteristics of a mesoionic ribose metabolite. Drug Metab Dispos. 1993;21:162-170. (Pubitemid 23052238)
12. Pilli HG, Safak C, Abbasoglu U. Sydnone derivatives: synthesis and antimicrobial activity. Arch Pharm (Weinheim). 1993;326:559-561. (Pubitemid 23287146)
13. Grynberg N, Santos AC, Echevarria A. Synthesis and in vivo antitumor activity of new heterocyclic derivatives of the 1,3,4-thiadiazolium-2-aminide class. Anticancer Drugs. 1997;8:88-91. (Pubitemid 27064755)
14. Vilpo JA, Vilpo LM, Vuorinen P, Moilanen E, Metsa-Ketela T. Mode of cytostatic action of mesoionic oxatriazole nitric oxide donors in proliferating human hematopoietic cells. Anticancer Drug Des. 1997;12:75-89. (Pubitemid 27149693)
15. Senff-Ribeiro A, Echevarria A, Silva EF, Sanches Veiga S, Oliveira MB. Effect of a new 1,3,4-thiadiazolium mesoionic compound (MI-D) on B16-F10 murine melanoma. Melanoma Res. 2003;13:465-471.
16. Senff-Ribeiro A, Echevarria A, Silva EF, Franco CR, Veiga SS, Oliveira MB. Cytotoxic effect of a new 1,3,4-thiadiazolium mesoionic compound (MI-D) on cell lines of human melanoma. Br J Cancer. 2004;91:297-304.
17. Shinzato TO, Grynberg N, Gomes RM, Echevarria A, Miller J. Antitumor activity of new mesoionic compounds against three murine tumors. Med Sci Res. 1989;17:865-866. (Pubitemid 19263672)
18. Majid PA, DeFeyter PJF, Van der Wall EE, Wardeh R, Ross JP. Molsidomine in the treatment of patients with angina pectoris. N Engl J Med. 1980;302:1-6.
19. Rudolph W, Derschinger J. Clinical comparation of nitrates and sydnonimines. Eur Heart J. 1991;12:33-41.
20. Karup G, Preikschat H, Wilhelmsen ES, Pedersen SB, Marcinkiewicz E, Cieslik K, et al. Mesoionic oxatriazole derivatives a new group of NO-donors. Pol J Pharmacol. 1994;46:541-552.
21. Kankaanranta H, Rydell E, Petersson AS, Holm P, Moilanen E, Corell T, et al. Nitric oxide-donating properties of mesoionic 3-aryl substituted oxatriazole-5-imine derivatives. Br J Pharmacol. 1996;117:401-406. (Pubitemid 126423559)
22. Mombouli J, Vanhoutte PM. Endothelium-derived hyperpolarizing factor(s): updating the unknown. Trends Pharmacol Sci. 1997;18:252-256. (Pubitemid 27296850)
23. Altura BM, Altura BT. Differential effects of substrate depletion on druginduced contractions of rabbit aorta. Am J Physiol. 1970;219:1698-1705.
24. Furchgott RF, Zawadzki JV. The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine. Nature. 1980:288:373-376. (Pubitemid 11169009)
25. Moncada S, Higgs EA. The L-arginine - nitric oxide pathway. N Eng J Med. 1993;329:2002-2012.
26. Toda N, Okamura T. The pharmacology of nitric oxide in the peripheral nervous system of bood vessels. Pharmacol Rev. 2003;55:271-324. (Pubitemid 36666049)
27. Garthwaite J, Southam E, Boulton CL, Nielsen EB, Schmidt K, Mayer B. Potent and selective inhibition of nitric oxide-sensitive guanylyl cyclase by 1H-[1,2,4] oxadiazolo [4,3-a] quinoxalin-1-one. Mol Pharmacol. 1995;48:184-188.
28. + channels in mediating heterogeneous microvascular responses to acethylcholine in different vascular beds. J Pharmacol Exp Ther. 1997;282:1473-1479.
29. Chen G, Suzuki H, Weston AH. Acetylcholine releases endothelium-derived hyperpolarizing factor and EDRF from rat blood vessels. Br J Pharmacol. 1988;95:1165-1174. (Pubitemid 19001158)
30. Moncada S, Palmer RMJ, Higgs EA. Nitric oxide: physiology, pathophysiology and pharmacology. Pharmacol Rev. 1991;43:109-142.
31. Shiraki H, Kawasaki H, Tezuka S, Nakatsuma A, Nawa H, Araki H, et al. Adrenergic nervs mediate acetylcholine-induced endothelium-independent vasodilation in the rat mesenteric resistance artery. Eur J Pharmacol. 2001;419:231-242. (Pubitemid 32568223)
32. Braman RS, Hendrix SA. Nanogram nitrite and nitrate determination in environmental and biological materials by vanadium (III) reduction with chemiluminescence detection. Analyt Chem. 1989;61:2715-2718. (Pubitemid 20065839)
33. Widlansky ME, Gokce N, Keaney JF, Vita JA. The clinical implications of endothelial dysfunction. J Am Coll Cardiol. 2003;42:1149-1160. (Pubitemid 37188333)
34. Palmer RM, Ferrige AG, Moncada S. Nitric oxide release accounts for the biological activity of endothelium-derived relaxing factor. Nature. 1988;327:524-526.
35. Gryglewski RJ, Moncada S, Palmer RM. Bioassay of prostacyclin and endothelium-derived relaxing factor (EDRF) from porcine aortic endothelial cells. Br J Pharmacol. 1986;87:685-694. (Pubitemid 16047532)
36. Nakane M, Mitchell J, Förstermann U, Murad F. Phosphorylation by calcium calmodulin-dependent protein kinase II and protein kinase C modulates the activity of nitric oxide synthase. Biochem Biophys Res Commun. 1991;180:1396-1402.
37. Bredt DS, Ferris CD, Snyder SH. Nitric oxide synthase regulatory sites: phosphorylation by cyclic AMP-dependent protein kinase, protein kinase C, and calcium/calmodulin protein kinase; identification of flavin and calmodulin binding sites. J Biol Chem. 1992;267:10976-10981.
38. Yi-Ching L, Huei-Hsia T, Rong-Jyh L, Deng-Chyang W, Bin-Nan W, Young-Tso L, et al. Endothelium-dependent and -independent vasorelaxation by a theophylline derivative MCPT: roles of cyclic nucleotides, potassium channel opening and phosphodiesterase inhibition. Life Sci. 2005;76:931-944. (Pubitemid 39601896)
39. Brophy CM, Knoepp L, Xin J, Pollock JS. Functional expression of NOS 1 in vascular smooth muscle. Am J Physiol Heart Circ Physiol. 2000;278:991-997. (Pubitemid 30152557)
40. Arnold WP, Mittal CK, Katsuki S, Murad F. Nitric oxide activates guanylate cyclase and increases guanosine 3′,5′-cyclic monophosphate levels in various tissue preparations. Proc Natl Acad Sci U S A. 1997;74:3203-3207. (Pubitemid 8180317)
41. Lowenstein CJ, Dinerman JL, Snyder SH. Nitric oxide: a physiology messenger. Ann Intern Med. 1994;120:227-237.
42. Vane JR, Anggard EE, Botting RM. Regulatory function of the vascular endothelium. N Eng J Med. 1990;323:27-36.
43. Eglen RM, Whiting R. Determination of the muscarinic receptor subtype mediating vasodilatation. Br J Pharmacol. 1985;84:3-5. (Pubitemid 15169050)
44. Caulfield MP. Muscarinic receptors: Characterization, coupling and function. Pharmacol Ther. 1993;58:319-379. (Pubitemid 23273186)
45. Rapoport RM. Cyclic guanosine monophosphate inhibition of contraction may be mediated through inhibition of phosphatidylinositol hydrolysis in rat aorta. Circ Res. 1986;58:407-410. (Pubitemid 16120766)
46. Archer SL, Huang JMC, Hampl V, Nelson DP, Shultz PJ, Weir EK. Nitric oxide and cGMP cause vasorelaxation by activation of a charybdotoxin-sensitive K channel by cGMP-dependent protein kinase. Proc Natl Acad Sci U S A. 1994;91:7583-7587. (Pubitemid 24238229)
47. López-Ramos JC, Martínez-Romero R, Molina F, Cañuelo A, Martínez-Lara E, Siles E, et al. Evidence of a decrease in nitric oxide-storage molecules following acute hypoxia and/or hypobaria, by means of chemiluminescence analysis. Nitric Oxide. 2005;13:62-67. (Pubitemid 40853970)
48. Li J, Bian KA, Bukoski RD. A non-cyclo-oxygenase, non-nitric oxide relaxing factor is present in resistance arteries of normotensive but not spontaneously hypertension rats. Am J Med Sci. 1994;307:7-14.
49. Vetrovsky P, Boucher JL, Schott C, Beranova P, Chalupsky K, Callizot N, et al. Involvement of NO in the endothelium-independent relaxing effects of N(omega)-hydroxy-L-arginine and other compounds bearing a C = NOH function in the rat aorta. J Pharmacol Exp Ther. 2002;303:823-830. (Pubitemid 35231259)
50. Cadena SM, Carnieri EG, Echevarria A, de Oliveira MB. Interference of MI-D, a new mesoionic compound, on artificial and native membranes. Cell Biochem Func. 2002;20:31-37. (Pubitemid 34178180)